Skip to content
Therapy But Better – Lifestyle
Author:
HepaRegeniX
HepaRegeniX Receives Orphan Drug Designation for Darizmetinib for the Prevention of Post-Hepatectomy Liver Failure
August 26, 2026
HepaRegeniX to Present Interim Phase 1b Data for Darizmetinib (HRX215) in a Late-Breaking Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2026
May 13, 2026